论文部分内容阅读
目的:探讨阿司匹林在动脉硬化性心脑血管疾病治疗中的应用价值。方法:选取我院内科于2015年1月至2015年12月期间收治的100例动脉硬化性心脑血管疾病患者作为本组研究的观察对象,采用平行随机抽样法将其分为对照组与观察组各50例;对照组给予学者用药方案治疗,观察组在常规用药方案的基础上联合阿司匹林口服治疗,观察期半年,对比两组的心脑血管事件的发生率、血小板凝聚率以及血栓素B2水平的变化情况。结果:(1)观察期间,观察组共发生心脑血管事件5例,发生率为10%;对照组共发生心脑血管事件13例,发生率为26%,观察组明显低于对照组,具有统计学意义P<0.05;(2)治疗后,观察组的血小板凝聚率与血栓素B2水平分别为(75.52±11.63)%与(97.58±18.54)pg/L,均明显低于对照组,具有统计学意义P<0.05。结论:在动脉硬化性心脑血管疾病的治疗中辅以阿司匹林,可以明显减少心脑血管风险事件的发生,具有明显的抗血栓效果,可以作为临床治疗与预防用药在临床中推广。
Objective: To investigate the value of aspirin in the treatment of arteriosclerotic cardiovascular and cerebrovascular diseases. Methods: A total of 100 patients with arteriosclerotic cardiovascular and cerebrovascular diseases admitted to our hospital from January 2015 to December 2015 were selected as the observation subjects in this study. They were divided into control group and observation by parallel random sampling The control group was treated with the medication regimen. The observation group was treated with aspirin orally on the basis of the conventional medication regimen, and the observation period was six months. The incidence of cardiovascular and cerebrovascular events, platelet aggregation rate, and thromboxane B2 The level of change. Results: (1) During the observation period, there were 5 cases of cardiovascular and cerebrovascular events in the observation group, the incidence was 10%; 13 cases of cardiovascular and cerebrovascular events occurred in the control group, the incidence was 26%, the observation group was significantly lower than the control group, (P <0.05). (2) After treatment, the platelet aggregation rate and the thromboxane B2 level in the observation group were (75.52 ± 11.63)% and (97.58 ± 18.54) pg / L respectively, which were significantly lower than those in the control group With statistical significance P <0.05. Conclusion: In the treatment of arteriosclerotic cardiovascular and cerebrovascular diseases, aspirin supplemented with aspirin can significantly reduce the risk of cardiovascular and cerebrovascular events, has obvious anti-thrombotic effect, and can be used as clinical treatment and prophylaxis in the clinical promotion.